All In Biotech

Drug Trial Radar · NCT07812090

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

A Randomized, Double-Masked, Multicenter Phase 2 Study Evaluating the Efficacy, Safety, and Tolerability of Oral BGE-102 as Mono- and Combination Therapy in Participants With Center-Involved Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
BioAge Labs, Inc.Industry
Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME). BGE-102 decreases inflammation which may improve vision or slow the progression of vison loss in those with CI-DME. Participants will be randomized to one of 3 arms and receive either BGE-102 in combination with an anti-vascular endothelial growth factor (anti-VEGF) drug, BGE-102 in combination with sham injection, or BGE-102 placebo in combination with an anti-VEGF drug. This study will also evaluate safety and tolerability of BGE-102.

Conditions

  • Diabetic Macular Edema (DME)

Interventions

  • Oral BGE-102Drug

    Capsules

  • Oral Placebo Matching BGE-102Drug

    Capsules

  • Anti-VEGFDrug

    intravitreal injection

  • ShamOther

    intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Best Corrected Visual Acuity (BCVA)Time frame: Week 12

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Site 104

    Bakersfield, California · Recruiting

  • Site 105

    Glendale, California · Recruiting

  • Site 118

    Mountain View, California · Recruiting

  • Site 128

    Fort Myers, Florida · Recruiting

  • Site 113

    South Miami, Florida · Recruiting

  • Site 119

    West Monroe, Louisiana · Recruiting

  • Site 117

    Cary, North Carolina · Recruiting

  • Site 116

    Wake Forest, North Carolina · Recruiting

  • Site 101

    Ladson, South Carolina · Recruiting

  • Site 111

    Abilene, Texas · Recruiting

  • Site 129

    Austin, Texas · Recruiting

  • Site 130

    Houston, Texas · Recruiting

  • Site 125

    Laredo, Texas · Recruiting

  • Site 106

    McAllen, Texas · Recruiting

  • Site 110

    San Antonio, Texas · Recruiting

  • Site 108

    The Woodlands, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.